The Weekly Litigation News Digest is now live. Subscribe now
Tablets Comprising Glp-1 Agonist And Enteric Coating - EP3250191
The patent EP3250191 was granted to Novo Nordisk on Jan 17, 2024. The application was originally filed on Jan 28, 2016 under application number EP16701684A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP3250191
- Application Number
- EP16701684A
- Filing Date
- Jan 28, 2016
- Status
- Granted And Under Opposition
- Dec 15, 2023
- Publication Date
- Jan 17, 2024
- External Links
- Slate, Register, Google Patents
Patent Summary
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (9) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents